Chatalic et al. [100] reported the 111In-DTPA-labeled engineered expression-modified nanobody JVZ-007, with a myc-tag and cys tag (111In-JVZ007-c-myc-his and 111InJVZ007-cys), which displayed good PSMA-positive tumor-targeting capability with rapid blood clearance in vivo. This evidence concerns the gene MYC and neoplasm.